Stoke Therapeutics, Inc. (STOK)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$233.3M
Cash & Equivalents
$60.6M
Quarterly Burn Rate
12 mo
Est. Cash Runway
$1,959M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT04740476 An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome PHASE2 Active Not Recruiting 60

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for STOK.

SEC EDGAR Filings

All SEC filings for Stoke Therapeutics, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.